The role of pro-resolving mediators in cancer cachexia
OA Version
Citation
Abstract
Cancer cachexia is a complex and multifactorial syndrome characterized by persistent inflammation, leading to severe muscle wasting, weight loss, and metabolic dysfunction. Conventional anti-inflammatory approaches have exhibited limited efficacy in effectively managing patient outcomes, emphasizing the importance of targeted therapies that resolve inflammation rather than merely suppressing it. However, special pro-resolving mediators (SPMs) recently described, including Resolvin D1 (RvD1) and Maresins, have emerged as potential candidates to combat inflammation-induced muscle degradation. In this study, the authors investigate the role of SPMs in the control of the key inflammatory pathways, e.g., NF-κB and JAK-STAT signaling, to attenuate cachexia-induced tissue atrophy. SPMs were assessed on systemic cytokine expression, muscle preservation, and tumor-induced inflammation using murine models of pancreatic and gastric cancer.The study results reveal that SPMs suppress the production of proinflammatory cytokines, prevent the degradation of muscle, and promote the resolution of inflammation. Hence, the study suggests that SPMs are potential candidates as therapeutic interventions for cancer cachexia. Nevertheless, many challenges stand between utilizing these insights in clinical applications. The reduced SPMs stability and bioavailability makes SPMs an ideal candidate for advanced delivery systems like nanovesicles (NVs) for improving their stability and therapeutic efficacy. Murine models are also very useful in providing mechanistic insights, but their metabolic and immune responses may not be identical to human responses. Future studies should determine the optimal delivery strategies of SPM, perform long-term in-vivo studies, as well as evaluate their combination with standard cancer treatments like chemotherapy and immunotherapy. Efforts to address these challenges are crucial to leverage SPM-based interventions for improving clinical outcomes for cancer cachexia patients.
Description
2025
License
Attribution 4.0 International